Interim GALAXY Phase 2b lung cancer study results to be presented at APLCC 2012

Published on November 26, 2012 at 9:44 AM · No Comments

Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced today that interim results of the Phase 2b portion of the GALAXY program will be presented on November 28, 2012 at 12:15 p.m. (JST) during the "Highlights of Oral Presentations" session at the Fifth Asia Pacific Lung Cancer Conference (APLCC 2012) in Fukuoka City, Japan. Dr. Christian Manegold, Professor of Medicine and head of Interdisciplinary Thoracic Oncology in the Department of Surgery at University Medical Center Mannheim, Heidelberg University, in Mannheim, Germany, will present the data, focusing on prior results highlighted at the 2012 Congress of the European Society for Medical Oncology (ESMO) last September.

The 800-patient Phase 2b/3 GALAXY program is designed to compare single agent docetaxel versus docetaxel plus ganetespib, a potent and selective Hsp90 inhibitor, as second-line treatment of advanced non-small cell lung cancer.

Source Synta Pharmaceuticals

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post